analysis, defining the "intervention" group as adults aged 19 to 25 years and the control group as adults aged 26 to 34 years. We excluded 2010 as a washout period; 2011 was the postimplementation period.
Binary outcomes were having health insurance; having any outpatient visit, primary care physician visit, emergency department visit, hospitalization, or prescription medicine fill within the past 12 months; and reporting excellent physical and mental health. Continuous outcomes were inflationadjusted annual health care expenditures, annual out-ofpocket expenditures, and percentage of expenditures paid outof-pocket.
We fitted models predicting outcomes as a function of intervention group status, postimplementation year status, and their interaction (the population-level differences-indifferences estimate). We used linear models for binary outcomes and percentage of expenditures paid out-of-pocket. For dollar-value expenditure outcomes, we used a 2-part model: a linear model predicting the probability of any expenditures and a linear model predicting log-transformed expenditures among individuals with any expenditures.
We tested for diverging preimplementation trends in outcomes between groups. Regressions controlled for sex, selfreported race/ethnicity, marital status, Census region, and urban residence. We used SAS version 9.3 (SAS Institute Inc), sampling weights, and robust design-based variance estimators. We considered 2-sided P<.05 to indicate statistical significance.
Results | The sample included 26 453 individuals in the intervention group and 34 052 in the control group. Overall, the sample was 46.6% male and 73.9% white. Group demographics were similar, except fewer adults in the intervention group were married (17.6% vs 56.1% in the control group). Compared with the control group, the dependent coverage provision was associated with an increase of 7.2 (95% CI, 4.2-10.2) percentage points in the probability of insurance coverage among adults aged 19 to 25 years (P < .001), no statistically significant changes in health care use, an increase of 6.2 (95% CI, 3.2-9.3) percentage points in the probability of reporting excellent physical health (P < .001), and an increase of 4.0 (95% CI, 0.6-7.5) percentage points in the probability of reporting excellent mental health (P = .02) ( Table 1) .
Compared with the control group, implementation of the provision was associated with a decrease of 3.7 (95% CI, 0.9-6.4) percentage points in the percentage of expenditures paid out-of-pocket among adults aged 19 to 25 years with any expenditures (P = .009; Table 2 ). Annual out-of-pocket expenditures declined by approximately 18% (95% CI, 5%-31%) in the intervention group (from an unadjusted mean of $546.11), relative to the control group (P = .006). Results were similar after additionally controlling for household income, education, and employment. Preimplementation trends did not differ significantly between groups.
Discussion | The dependent coverage provision was associated with improved self-reported health and protection against medical costs among adults aged 19 to 25 years compared with older adults unaffected by the law. One recent study indicated that the provision was associated with improved protection against emergency care costs; we found this financial protection extended to overall medical expenditures.
4 Previous research documented rapid improvements in selfreported health among low-income and elderly adults gaining Medicaid and Medicare coverage, respectively. 5, 6 In one study, these gains occurred before any changes in health care use, suggesting that insurance may improve peace of mind and perceptions of health.
5
We did not detect significant changes in health care use; however, only 1 year of postimplementation data was available for our study, which limited statistical power and prevented examination of longer-term changes. Another limitation is that other factors during the postimplementation period could have differentially affected outcomes between groups. b Adjusted coefficient of the interaction between postimplementation status and intervention group. Estimates for log annual expenditures and log out-of-pocket expenditures represent the net change in log expenditures, which approximates the relative change in expenditures (in percentage terms) for the intervention group compared with the control group. All other estimates represent percentage point changes. c The values in columns 2-5 are unadjusted percentages.
Kao
d For descriptive purposes, unadjusted dollar value expenditures are presented.
However, for regression analyses estimating the policy effect, log-transformed expenditures were modeled due to the skewness of the expenditure data. e Among individuals with nonzero annual health care expenditures (n = 42 092). f Among individuals with nonzero annual out-of-pocket health care expenditures (n = 37 808). 
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COMMENT & RESPONSE
Number of Human Papillomavirus Vaccine Doses and Condyloma
To the Editor Dr Herweijer and colleagues 1 presented shortterm data on the association of quadrivalent human papillomavirus (HPV) vaccine with the risk of condyloma by number of vaccine doses. Their primary analysis showed that fewer doses may be associated with a reduction in condyloma risk, albeit with less reduction than 3 doses. Yet their supplemental data suggested that 1 and 2 doses may be associated with comparable risk reduction as 3 doses. We would like to address this inconsistency. Reduced-dose schedules could diminish disparities related to access to HPV vaccines by easing costs and logistics; the hope is this would translate to greater uptake in resourcepoor settings. If 1 dose allows for greater vaccine uptake, it may be able to prevent more deaths than 2 doses, even if modestly inferior. Data from the Costa Rica Vaccine Trial, which used the bivalent HPV vaccine, showed comparable vaccine efficacy against incident persistent HPV 16/18 infections after 4 years for women who received 1, 2, or 3 doses 2 ; within the same study, immunogenicity data bolstered this observation by showing stable antibody levels by dose against HPV 16/18.
3 Responses for 1 dose were lower although higher than those observed for natural immunity. Immunogenicity data showing comparable antibody titers for 2 and 3 doses have also been published. 4 Ideally, risk reductions or vaccine efficacy should be assessed among vaccine recipients prior to sexual debut, to avoid misclassifying as vaccine failures HPV infections prevalent at time of vaccination, which are not affected by vaccination.
5
In the current analysis, prevalent infections may have disproportionately affected girls receiving fewer than 3 doses: sensitivity analyses that accounted for cases occurring within months immediately after vaccination by lengthening the "buffer period" between vaccination and case counting showed a decrease in risk of condyloma, especially among the youngest girls most likely to have been recently exposed. Use of the 12-month buffer made the incident rate ratios (IRRs) for girls who received 1, 2, and 3 doses nearly identical (IRRs, 0.24, 0.19, and 0.19 , respectively) compared with unvaccinated girls (eTable 1 in the Supplement for the article). One potential conclusion is that individuals who did not receive the full 3-dose schedule obtained similar risk reduction.
We look forward to future work with more person-time that is restricted to girls vaccinated before sexual debut, for whom risk or vaccine efficacy estimates will be nearly unaffected by prevalent HPV infections, and the durability of protection can be assessed.
Aimée R. Kreimer, PhD Mahboobeh Safaeian, PhD Allan Hildesheim, PhD
